Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine

Journal of Clinical Virology

Volumn 31, Issue 1, 2004, Pages 53-57

  Zanati, Simon A ^a   Locarnini, Stephen A ^b   Dowling, John P ^a   Angus, Peter W ^c   Dudley, Francis J ^a   Roberts, Stuart K ^a  

^a ALFRED HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

Chloroquine; Fibrosing cholestatic hepatitis; Hepatitis B pre S mutant; Prednisolone

Indexed keywords

ANTIBIOTIC AGENT; CHLOROQUINE; CORTICOSTEROID; HYDROCORTISONE; HYDROXYCHLOROQUINE; LAMIVUDINE; PREDNISOLONE; VIRUS DNA;

ADULT; ANAMNESIS; ARTICLE; BLOOD CULTURE; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DRUG MEGADOSE; EARLY DIAGNOSIS; FEMALE; FIBROSING CHOLESTATIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOPEROXIDASE STAINING; LABORATORY TEST; LAPAROTOMY; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MENINGITIS; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS DETECTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; CHLOROQUINE; CHOLESTASIS; FATAL OUTCOME; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; LIVER; LIVER FAILURE; MIXED CONNECTIVE TISSUE DISEASE; MUTATION; PREDNISOLONE;

EID: 3543150780     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.02.013     Document Type: Article

References (18)

1. Bock C.T., Tillmann H.L., Maschek H.J., Manns M.P., Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology. 113:1997;1976-1982
2. Davies S.E., Portmann B.C., O'Grady J.G., Aldis P.M., Chaggar K., Alexander G.J., Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 13:1991;150-157
3. Fang J.W., Wright T.L., Lau J.Y. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B [letter]. Lancet. 342:1993;1175
4. Flowers M., Heathcote J., Wanless I., Sherman M., Reynolds W., Cameron R., Levy G., et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann. Intern. Med. 112:1990;381-382
5. Hawkins A.E., Gilson R.J., Gilbert N., Wreghitt T.G., Gray J.J., Ahlers-de Boer I., Tedder R.S., et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J. Hepatol. 24:1996;8-14
6. Kouroumalis E.A., Koskinas J. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann. Acad. Med. Singapore. 15:1986;149-152
7. Lam P., Wachs M., Somberg K., Vincenti F., Lake J., Ferrell L. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 61:1996;378-381
8. Lau J.Y., Bain V.G., Davies S.E., O'Grady J.G., Alberti A., Alexander G.J., et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology. 102:1992a;956-962
9. Lau J.Y., Bain V.G., Smith H.M., Alexander G.J., Williams R. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation. 53:1992b;894-898
10. Liang T.J., Hasegawa K., Rimon N., Wands J.R., Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis [see comments]. N. Engl. J. Med. 324:1991;1705-1709
11. McCaughan G.W., Spencer J., Koorey D., Bowden S., Bartholomeusz A., Littlejohn M., et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl. Surg. 5:1999;512-519
12. McIvor C., Morton J., Bryant A., Cooksley W.G., Durrant S., Walker N. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann. Intern. Med. 121:1994;274-275
13. McMillan J.S., Bowden D.S., Angus P.W., McCaughan G.W., Locarnini S.A. Mutations in the hepatitis B virus precore/core gene promoter in patients with severe recurrent disease following liver transplantation. Hepatology. 24:1996;1371-1378
14. Melegari M., Bruno S., Wands J.R. Properties of hepatitis B virus pre-S1 deletion mutants. Virology. 199:1994;292-300
15. Shaw T., Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology. 32:2000;430-432
16. Trautwein C., Schrem H., Tillmann H.L., Kubicka S., Walker D., Boker K.H., et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology. 24:1996;482-488
17. Tur-Kaspa R., Burk R.D., Shaul Y., Shafritz D.A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl. Acad. Sci. U.S.A. 83:1986;1627-1631
18. Xu Z., Yen T.S. Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J. Virol. 70:1996;133-140